A hybrid model for hepatitis B virus

[1]  จารุภา ตั้งก่อพันธุ์.  Peginterferon alfa 2b , 2012, Reactions weekly.

[2]  Luonan Chen,et al.  Coexpression network analysis in chronic hepatitis B and C hepatic lesions reveals distinct patterns of disease progression to hepatocellular carcinoma. , 2012, Journal of molecular cell biology.

[3]  Matthew Kowgier,et al.  Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. , 2010, Gastroenterology.

[4]  F. Zoulim,et al.  Hepatitis B virus: from diagnosis to treatment. , 2010, Pathologie-biologie.

[5]  Yang Kuang,et al.  The dynamics of a delay model of hepatitis B virus infection with logistic hepatocyte growth. , 2009, Mathematical biosciences and engineering : MBE.

[6]  Lequan Min,et al.  Mathematical Analysis of a Basic Virus Infection Model With Application to HBV Infection , 2008 .

[7]  Yang Kuang,et al.  Dynamics of a delay differential equation model of hepatitis B virus infection , 2008, Journal of biological dynamics.

[8]  T. Liang,et al.  Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. , 2007, Gastroenterology.

[9]  F. Zoulim,et al.  A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine , 2006, Journal of viral hepatitis.

[10]  R. Purcell,et al.  Dynamics of hepatitis B virus clearance in chimpanzees. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[12]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[13]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[14]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[15]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[16]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Watmough,et al.  Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. , 2002, Mathematical biosciences.

[18]  Ruy M Ribeiro,et al.  Dynamics of hepatitis B virus infection. , 2002, Microbes and infection.

[19]  A. Perelson.  Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[20]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[21]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.